Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.28 SEK | -2.32% | -9.73% | +175.37% |
May. 16 | Transcript : Ascelia Pharma AB, Q1 2024 Earnings Call, May 16, 2024 | |
May. 16 | Ascelia Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 313M 29.24M |
---|---|---|---|---|---|
Net income 2024 * | -37M -3.45M | Net income 2025 * | -102M -9.52M | EV / Sales 2024 * | - |
Net cash position 2024 * | 15.7M 1.47M | Net cash position 2025 * | 7M 653K | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.22
x | P/E ratio 2025 * |
-3.6
x | Employees | 13 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.72% |
Latest transcript on Ascelia Pharma AB
1 day | -2.32% | ||
1 week | -9.73% | ||
Current month | -12.29% | ||
1 month | -33.24% | ||
3 months | +10.74% | ||
6 months | +220.55% | ||
Current year | +175.37% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 13-12-31 | |
Director of Finance/CFO | 52 | 19-12-31 | |
Chief Tech/Sci/R&D Officer | 40 | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 69 | 17-05-31 | |
Niels Mengel
BRD | Director/Board Member | 76 | 99-12-31 |
Director/Board Member | 59 | 16-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 9.28 | -2.32% | 270,973 |
24-05-16 | 9.5 | -6.68% | 145,382 |
24-05-15 | 10.18 | +5.49% | 113,101 |
24-05-14 | 9.65 | -3.50% | 126,409 |
24-05-13 | 10 | -2.72% | 208,330 |
Delayed Quote Nasdaq Stockholm, May 17, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+175.37% | 29.26M | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- ACE Stock